IP Library Granted Patent US 7,838,562
Granted Patent B2
US 7,838,562 · App. 10/562,305 · Granted Nov 23, 2010

Methods of inhibiting vascular permeability and apoptosis

Assignee: University of Connecticut
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,562
App. No.
10/562,305
Granted
Nov 23, 2010
Kind
B2
Abstract

Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.

Claims (3)

1. A method of treating a mammal in need of treatment for a vascular permeability disorder, comprising administering to the mammal in need of treatment for a vascular permeability disorder a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol,

wherein the vascular permeability disorder is increased vascular permeability associated with endothelial injury, thrombocytopenia, ischemic peripheral vascular disease, a peripheral vascular disorder associated with diabetes, Dengue hemorrhagic fever, acute respiratory distress syndrome, vascular leak syndrome, or a combination comprising one or more of the foregoing disorders.

2. A method of treating a mammal in need of treatment for acute respiratory distress syndrome, comprising administering to the mammal in need of treatment for acute respiratory distress syndrome a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 7, 2011
From: UNIVERSITY OF CONNECTICUT HEALTH CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026553/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2007
From: HLA, TIMOTHY; SANCHEZ, TERESA; CLAFFEY, KEVIN PATRICK; PAIK, JI-HYE
To: UNIVERSITY OF CONNECTICUT
Reel/Frame 018988/0206 →
Continuity (1)
Related Publication 20080039530A1 · Feb 14, 2008